Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
Company profile
Ticker
ALBO
Exchange
Website
CEO
Gary Gemignani
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Biodel Inc
SEC CIK
Corporate docs
Subsidiaries
Albireo AB, a limited liability company • Elobix AB, a limited liability company • Albireo Pharma Limited, a limited liability company • Albireo Pharma Security Corporation ...
ALBO stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
14 Mar 23
EFFECT
Notice of effectiveness
9 Mar 23
EFFECT
Notice of effectiveness
9 Mar 23
EFFECT
Notice of effectiveness
9 Mar 23
EFFECT
Notice of effectiveness
9 Mar 23
EFFECT
Notice of effectiveness
9 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Mar 23
Transcripts
ALBO
Earnings call transcript
2022 Q3
9 Nov 22
ALBO
Earnings call transcript
2022 Q2
16 Aug 22
ALBO
Earnings call transcript
2022 Q1
17 May 22
ALBO
Earnings call transcript
2021 Q4
1 Mar 22
ALBO
Earnings call transcript
2021 Q3
4 Nov 21
ALBO
Earnings call transcript
2021 Q2
7 Aug 21
ALBO
Earnings call transcript
2021 Q1
8 May 21
ALBO
Earnings call transcript
2020 Q4
26 Feb 21
ALBO
Earnings call transcript
2020 Q2
8 Aug 20
ALBO
Earnings call transcript
2020 Q1
10 May 20
Latest ownership filings
SC 13G/A
Deep Track Capital, LP
14 Feb 24
SC 13G/A
FEDERATED HERMES, INC.
10 Apr 23
SC 13G/A
BlackRock Inc.
8 Mar 23
4
David Chiswell
3 Mar 23
4
Susan Alesina
2 Mar 23
4
Stephanie Okey
2 Mar 23
4
Simon N.R. Harford
2 Mar 23
4
Ronald Harold Wilfred Cooper
2 Mar 23
4
PAUL STRECK
2 Mar 23
4
Pamela Stephenson
2 Mar 23
Financial summary
Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 272.48 mm | 272.48 mm | 272.48 mm | 272.48 mm | 272.48 mm | 272.48 mm |
Cash burn (monthly) | (no burn) | (no burn) | 12.60 mm | 10.78 mm | 9.88 mm | 9.61 mm |
Cash used (since last report) | n/a | n/a | 235.00 mm | 200.98 mm | 184.21 mm | 179.24 mm |
Cash remaining | n/a | n/a | 37.48 mm | 71.50 mm | 88.27 mm | 93.24 mm |
Runway (months of cash) | n/a | n/a | 3.0 | 6.6 | 8.9 | 9.7 |
Institutional ownership, Q3 2023
6.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 0 |
Closed positions | 1 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 43.73 mm |
Total shares | 1.41 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Ics Opportunities | 999.36 k | $43.73 mm |
Tang Capital Partners | 411.97 k | $0.00 |
Proequities | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Mar 23 | Hopkinson Craig C. | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 10,495 | 0.00 | 0 |
2 Mar 23 | Scoon Davey | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 9 | 3,333 | 30.00 k | 0 |
2 Mar 23 | Scoon Davey | Stock Option (right to buy)) Common Stock | Sale back to company | Dispose D | No | No | 39.6 | 333 | 13.19 k | 0 |
2 Mar 23 | Scoon Davey | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 18.54 | 4,500 | 83.43 k | 0 |
2 Mar 23 | Scoon Davey | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 17.05 | 3,000 | 51.15 k | 0 |
2 Mar 23 | Scoon Davey | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 32.53 | 5,500 | 178.92 k | 0 |
2 Mar 23 | Scoon Davey | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 31.22 | 5,500 | 171.71 k | 0 |
2 Mar 23 | Scoon Davey | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 27.89 | 8,000 | 223.12 k | 0 |
2 Mar 23 | Scoon Davey | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 36.87 | 8,000 | 294.96 k | 0 |
2 Mar 23 | Scoon Davey | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 19.47 | 8,000 | 155.76 k | 0 |